Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026

Related Information
Company: Novo Nordisk

CagriSema REDEFINE 9 produced an estimated average weight loss of about 21% at 68 weeks in adults with overweight or obesity, Novo Nordisk announced on 14 November 2026 from Plainsboro, New Jersey, and Bagsværd, Denmark. The phase 3 trial evaluated investigational CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, at doses below the 2.4 mg / 2.4 mg maximum studied in the wider REDEFINE program. Results were presented at ObesityWeek® 2026 in Washington, DC, and published simultaneously in The Lancet Diabetes & Endocrinology.

According to the company, the CagriSema REDEFINE 9 study is the first phase 3 weight management trial to test CagriSema below the 2.4 mg / 2.4 mg dose. Two lower dose levels were evaluated, 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg, each compared with its own placebo comparison. Under the efficacy estimand, which reflects the treatment effect if all participants adhered to treatment, estimated average weight loss at week 68 was 20.7% and 21.0%, versus 2.0% with placebo.

Martin Holst Lange, Novo Nordisk’s executive vice president, chief scientific officer and head of Research & Development, called understanding how people respond across doses an “important part of obesity research.” He said the CagriSema REDEFINE 9 results add to knowledge of CagriSema across doses and, together with the broader REDEFINE program, inform how the company continues to develop the cagrilintide and semaglutide combination.

Lead author Dr. Sean Wharton of the Temerty Faculty of Medicine at the University of Toronto said participants on both doses lost significantly more weight than those on placebo. He said the findings have “potential to inform clinical practice,” where dosing is often adjusted to individual needs. This article reports those views as stated by the company and investigators. They are not regulatory conclusions.

CagriSema REDEFINE 9 Efficacy: Weight Loss, Responder Rates and Waist Circumference

In the CagriSema REDEFINE 9 efficacy analysis, a significantly higher proportion of adults reached body weight reductions of at least 5%, 10%, 15% and 20% on both doses than on placebo. With 1.7 mg / 1.7 mg, 95.1% achieved at least 5% weight loss and 51.3% achieved at least 20%. With 1.0 mg / 1.0 mg, the figures were 96.3% and 48.3%, compared with 33.4% and 2.7% for pooled placebo.

Advertisement

Waist circumference, a confirmatory secondary endpoint used to gauge abdominal fat, fell by 17.2 cm with CagriSema 1.7 mg / 1.7 mg and 17.5 cm with 1.0 mg / 1.0 mg, compared with 3.6 cm with placebo (p<0.0001 for both). Mean baseline body weight across the trial was 109.5 kg.

CagriSema REDEFINE 9 Efficacy: Weight Loss, Responder Rates and Waist Circumference

In the CagriSema REDEFINE 9 efficacy analysis, a significantly higher proportion of adults reached body weight reductions of at least 5%, 10%, 15% and 20% on both doses than on placebo. With 1.7 mg / 1.7 mg, 95.1% achieved at least 5% weight loss and 51.3% achieved at least 20%. With 1.0 mg / 1.0 mg, the figures were 96.3% and 48.3%, compared with 33.4% and 2.7% for pooled placebo.

Waist circumference, a confirmatory secondary endpoint used to gauge abdominal fat, fell by 17.2 cm with CagriSema 1.7 mg / 1.7 mg and 17.5 cm with 1.0 mg / 1.0 mg, compared with 3.6 cm with placebo (p<0.0001 for both). Mean baseline body weight across the trial was 109.5 kg.

Novo Nordisk stated that CagriSema REDEFINE 9 was not powered to detect differences between the two CagriSema doses. That caveat matters for interpretation. The closely matched results at 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg do not, on their own, establish that the doses are interchangeable, and the announcement does not claim they are.

Treatment Regimen Estimand: What CagriSema REDEFINE 9 Shows Regardless of Adherence

The treatment regimen estimand measures the effect regardless of treatment discontinuation or use of weight management rescue intervention, and it produced more conservative figures. Estimated average weight loss at week 68 was 19.4% with CagriSema 1.7 mg / 1.7 mg and 18.6% with 1.0 mg / 1.0 mg, compared with 4.6% with placebo. The estimated treatment differences were −14.7 and −13.9 percentage points (p<0.0001 for both).

Advertisement

On this measure, 92.8% of adults on the higher dose and 87.7% on the lower dose achieved at least 5% body weight reduction, versus 41.1% with placebo. Because CagriSema REDEFINE 9 data are reported under two estimands, readers should check which one a quoted figure comes from. The ~21% headline figure comes from the efficacy estimand.

CagriSema REDEFINE 9 Safety Profile and Trial Design

In CagriSema REDEFINE 9, Novo Nordisk reported that the safety profile at both doses was consistent with previous CagriSema trials. The most frequently reported adverse events were gastrointestinal and mild to moderate in severity. Adverse events leading to permanent treatment discontinuation occurred in 2.9% of adults on CagriSema 1.7 mg / 1.7 mg and 4.9% on 1.0 mg / 1.0 mg, compared with 4.9% on placebo.

The announcement did not provide event-by-event incidence rates, serious adverse event counts or laboratory findings, so these remain Not disclosed in the source material. Full safety tables should be consulted in the peer-reviewed paper in The Lancet Diabetes & Endocrinology before any clinical conclusion is drawn.

Related Leads